MaxCyte, Inc. provided revenue guidance for the year 2022. The company expects revenue from core business (instruments and disposables to cell therapy and drug discovery customers) to grow between 22% and 25% over 2021. The company also expect SPL Program-related revenue to be approximately $4 million in 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
377.6 GBX | -0.63% |
|
+0.69% | +7.12% |
Jun. 11 | MaxCyte CEO Maher Masoud buys 100,000 shares | AN |
Jun. 11 | Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.12% | 504M | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+0.95% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
-1.07% | 34.92B |
- Stock Market
- Equities
- MXCT Stock
- News MaxCyte, Inc.
- MaxCyte, Inc. Provides Revenue Guidance for the Year 2022